South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)

Enzychem Lifesciences

24/11/2021 09:29

(Adds executive comment, details, background)
    BENGALURU, Nov 24 (Reuters) - South Korea's Enzychem
Lifesciences  183490.KQ  would make at least 80 million doses of
India's homegrown DNA COVID-19 vaccine from Cadila Healthcare
 CADI.NS , the Indian drugmaker said on Wednesday.
    As part of the deal, Cadila will transfer the DNA vaccine
technology to Enzychem, which will make and sell the vaccine,
ZyCoV-D, within its territory under the Cadila trademark. Cadila
will get license fees and royalty payments, the company said in
a filing https://bit.ly/3HZz3a2 to stock exchanges.
    "(The DNA) technology allows vaccines to be produced at
affordable costs in record times, and DNA vaccines are
considerably stable," said Ki Young Sohn, chairman of Enzychem
Lifesciences.
    "ZyCoV-D is administered without needles and can be deployed
more readily, especially in resource-poor populations." 
    Cadila's vaccine, which is administered in three doses, was
approved by India's drug regulator in August for emergency use
in adults and children aged 12 years and above, though it has
yet to be rolled out as part of the county's vaccination drive.

 (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Arun
Koyyur and Shailesh Kuber)
 ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))